StockData
Verrica Pharmaceuticals Inc. logo

Verrica Pharmaceuticals Inc. (VRCA) company profile

VRCANasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 4/30
$3.14−0.06 (-1.88%)

Close on Nov 17, 2026Market cap $53.94MP/E –Yield –

About Verrica Pharmaceuticals

Pharmaceutical Preparations, SIC 2834

Verrica Pharmaceuticals is a clinical-stage and commercial therapeutics company focused on developing and commercializing clinician-administered medications for dermatologic diseases and skin cancers. Its primary commercial product is YCANTH, an FDA-approved topical formulation of cantharidin delivered via a single-use precision applicator for treating molluscum contagiosum. The company's development pipeline includes advancing YCANTH for the treatment of common warts, as well as developing VP-315, an investigational injectable peptide therapy for dermatological oncology conditions such as basal cell carcinoma. Its offerings primarily target pediatric dermatologists, general dermatologists, pediatricians, and other primary care health care providers.

The company operates primarily in the United States, where it employs a specialized sales organization of approximately 40 field sales representatives and contractors, and reaches approximately 250 million covered lives through insurance coverage determinations. Internationally, the company licenses commercial and development rights in Japan to Torii Pharmaceutical Co., Ltd. The provided text does not state the location of the company's headquarters.

Summary of the business section of Verrica Pharmaceuticals's latest annual report, written by StockData.

Company profile

Company

Legal name
Verrica Pharmaceuticals Inc.
Headquarters
West Chester, PA
Address
44 West Gay Street, Suite 400
Phone
(484) 453-3300
Employees
76, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
KPMG LLP, Philadelphia, PA

Stock & identifiers

Ticker
VRCA
Exchange
Nasdaq
IPO date
Jun 15, 2018
Shares outstanding
17M, Jul 31, 2026
Public float
$27.30M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-10 reverse, Jul 25, 2025
SEC CIK
1660334
CUSIP
92511W207
ISIN
US92511W2070
FIGI
BBG00L03BYB7
Share class FIGI
BBG00L03BZ24
LEI
5493002L68H6THU5GW50
EIN
46-3137900

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Jayson RiegerCEO and President, Director207,838
Ted WhitePRESIDENT AND CEO, Director278,789
John J. KirbyInterim CFO23,962
Noah L. RosenbergCMO8,587
David ZawitzChief Operating Officer27,000
Christopher G. HayesCHIEF LEGAL OFFICER176,458
Joe BonaccorsoCHIEF COMMERCIAL OFFICER187,738
Terry KohlerCHIEF FINANCIAL OFFICER125,000
Gary GoldenbergChief Medical Officer120,110
Diem NguyenDirector100
Gavin CorcoranDirector20
Lawrence EichenfieldDirector–
Mark A. Prygocki SrDirector–
Charles FrantzrebDirector–
Paul B. ManningDirector7,395,748
John A. Stalfort IIIDirector1,873,800

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025
Jayson Rieger
$741.40K$437.10K$905.73K$30–
FY2025
Ted White
$0$0$905.73K$30–
FY2024
Jayson Rieger
$1.24M$1.06M$1.19M$25–
FY2024
Ted White
$2.59M-$467.92K$1.19M$25–
FY2023
Jayson Rieger
$0$0$2.33M$266–
FY2023
Ted White
$3.50M$4.64M$2.33M$266–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsIncentive payOtherTotalvs. prior year
Jayson Rieger
President and Chief Executive Officer
$300.00K––$350.24K$74.38K$16.79K$741.40K-40%
John J. Kirby
Interim Chief Financial Officer
$480.00K$10.00K$82.10K–$42.50K–$614.60K+436%
Noah Rosenberg
Chief Medical Officer
$173.86K$25.00K–$139.05K–$9.68K$347.59K–
Christopher G. Hayes
Former Chief Legal Officer
$155.33K––$100.35K$10.00K$481.90K$747.58K-27%
Gary Goldenberg
Former Chief Medical Officer
$79.06K––$48.01K–$236.06K$363.13K-63%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jun 15, 2018
Offer price
$15.00
Securities offered
5,000,000
Gross proceeds
$75.00M
Exchange
Nasdaq
First trading day
Jun 15, 2018
First-day close
$17.50+16.7%
Lock-up ends (est.)
Dec 12, 2018

“Per Share Total Public offering price $15.00 $75,000,000 Underwriting discount(1) $1.05 $5,250,000 Proceeds, before expenses, to us $13.95 $69,750,000 (1) We refer you to “Underwriting” beginning on page 151 for additional information regarding underwriting compensation.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 76 full-time employees.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?